Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB-452 Following Oral Administration in Healthy Subjects and Subjects with Chronic Hepatitis B

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB-452 Following Oral Administration in Healthy Subjects and Subjects with Chronic Hepatitis B

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2018

At a glance

  • Drugs AB-452 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Arbutus Biopharma
  • Most Recent Events

    • 12 Nov 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 09 Oct 2018 According to an Arbutus Biopharma media release, the company expects Phase I initiation to be delayed as the company is working on completing ongoing non-clinical studies.
    • 28 Aug 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top